INmune Bio Inc. develops clinical-stage immunology and biotechnology treatments designed to target the innate immune system in disease. Company news commonly centers on three platforms: CORDStrom, a pooled allogeneic human umbilical cord-derived mesenchymal stromal/stem cell platform; XPro, a dominant-negative TNF platform intended to selectively neutralize soluble TNF; and INKmune, a cell-based medicine designed to prime natural killer cells against residual cancer.
Recurring updates include clinical and preclinical data, regulatory pathway discussions, manufacturing and collaboration agreements, conference presentations, shareholder communications, and quarterly or annual financial results. Coverage also reflects program areas such as recessive dystrophic epidermolysis bullosa, early Alzheimer’s disease, neuroinflammation, inflammatory disease and oncology.
INmune Bio, Inc. (NASDAQ: INMB) announced its President and CEO, Raymond J. Tesi, will present at the BIO CEO & Investor Conference in New York City from February 14-17, 2022. The presentation is scheduled for February 15 at 9:15 AM ET. Attendees can schedule virtual one-on-one meetings with the company during the conference. INmune Bio focuses on harnessing the innate immune system to develop treatments for diseases, with ongoing clinical trials for its product platforms, DN-TNF and NK Cell Priming.
INmune Bio (NASDAQ: INMB) has announced a pre-clinical research collaboration with the Chinese University of Hong Kong to evaluate its NK cell priming platform, INKmune™, in treating nasopharyngeal cancer (NPC). This partnership will leverage access to established NPC cancer cell lines. INMB's Chief Executive Officer, RJ Tesi, stated that this collaboration validates INKmune's versatility, targeting a cancer with high mortality rates and limited treatment options. The grant supports pre-clinical work, potentially leading to clinical trials in the UK, Hong Kong, and the US.
INmune Bio, a clinical-stage immunology company (NASDAQ: INMB), announced participation in upcoming investor conferences and a medical meeting. Key events include a panel discussion at LifeSci Advisors' 11th Annual Corporate Access Event on January 6, 2022, and a presentation at H.C. Wainwright Bioconnect Conference on January 10, 2022. Additionally, Professor Mark Lowdell will chair a session at the Allogeneic Cell Therapies Summit Europe on January 19, 2022. The company focuses on developing therapies that utilize the innate immune system to combat diseases such as cancer and Alzheimer’s.
INmune Bio (NASDAQ: INMB) presented data at the San Antonio Breast Cancer Symposium indicating that MUC4 expression is a key predictor of worse survival and treatment resistance in triple negative breast cancer (TNBC). The therapy INB03 can potentially reverse this resistance by reducing immunosuppression in the tumor microenvironment. Key findings show INB03 enhances macrophage phagocytosis and lymphocyte function, while decreasing TNBC's metastatic potential. The poster is presented by Dr. Roxana Schillaci on December 10, 2021, emphasizing the role of MUC4 in guiding combination therapies for improved patient outcomes.
INmune Bio, Inc. (NASDAQ: INMB) announced two poster presentations at the 2021 British Society of Immunology Congress. The presentations highlighted the mechanism of action of INKmune, demonstrating its ability to generate memory-like NK cells and promote their proliferation. Notably, a patient treated with INKmune showed a significant increase in NK cell activation post-treatment. The presentations could have important implications for cancer therapy, showcasing INKmune's potential in enhancing NK cell function against tumors.
INmune Bio, Inc. (NASDAQ: INMB) announced its second Phase 2 trial of XPro for Mild Cognitive Impairment (MCI), alongside a previously disclosed trial for mild Alzheimer’s disease (AD). The trial aims to include 90 patients and assess cognition using the Early AD/MCI Alzheimer's Cognitive Composite (EMACC). As of September 30, 2021, the company reported cash equivalents of $84.5 million and a net loss of approximately $9.5 million for Q3 2021. The firm is also advancing its INKmune™ platform and plans to host a conference call on November 3, 2021.
INmune Bio, Inc. (NASDAQ: INMB) is set to present multiple findings at the 14th Clinical Trials on Alzheimer’s Disease (CTAD) Annual Meeting, taking place from November 9-12 in Boston. Key presentations include a late-breaking oral presentation on the Early Mild Alzheimer’s Cognitive Composite as a primary cognitive endpoint in a phase 2 trial of XPro1595. Additionally, various poster sessions will examine neuroinflammation biomarkers, imaging measures, and methodologies for effective trial planning. XPro1595 aims to decrease neuroinflammation, potentially improving outcomes in Alzheimer's patients.
INmune Bio, Inc. (NASDAQ: INMB) announced a conference call scheduled for November 3, 2021 at 4:30 PM ET to discuss its third quarter results ending September 30, 2021, and provide a corporate update. The call will offer insights into the company’s clinical-stage immunology initiatives, including its DN-TNF and Natural Killer Cell Priming platforms. Investors can participate via phone or a live audio webcast, with a replay available until November 10. The company emphasizes the forward-looking nature of its statements regarding clinical trials and potential product approvals.
INmune Bio, Inc. (NASDAQ: INMB) announced that Mark Lowdell, PhD, Chief Scientific Officer and Chief Medical Officer, will participate in an oncology panel titled Improving Strategies to Harness the Immune System at the B. Riley Fall 2021 Best Ideas in Oncology Series.
The panel is scheduled for September 30, 2021, at 9:00am ET and is open to institutional investors. Registration is available here.
INmune Bio, Inc. (NASDAQ: INMB), a clinical-stage immunology company, announced that its President and CEO, Raymond J. Tesi, MD, will present at two investor conferences in September 2021. The Oppenheimer Fall Healthcare Life Sciences & MedTech Summit will take place on September 22 at 1:15 PM ET, followed by the Cantor Fitzgerald Global Healthcare Conference on September 29 at 3:20 PM ET. Investors can arrange virtual one-on-one meetings through Oppenheimer or Cantor Fitzgerald. INmune Bio develops treatments targeting the innate immune system for various diseases.